SHELTON, Conn., Sept. 19, 2017 -- 3Gtms, Inc., a global provider of Tier 1 transportation management software (TMS), announced that it has named Chris van der Harst to the new position of managing director, EMEA.
In this position, van der Harst will lead 3Gtms’ overseas efforts from its EMEA headquarters in Utrecht, The Netherlands. He will be responsible for growing 3Gtms’ market share among 3PLs and mid-large sized shippers, as well as ensuring 3Gtms’ industry-leading satisfaction rate is upheld among all customers. 3Gtms’ robust TMS gives 3PLs and shippers the most powerful and intuitive system for over-the-road and intermodal freight, along with best-in-class rating and optimization. The modern design enables flexible, seamless handling of the most complicated shipping requirements, covering the complete order-to-cash process.
A 30-year supply chain veteran with 20 years of global experience, van der Harst has been on both the user and provider side of logistics software. He was most recently managing director, EMEA at Kinaxis, and has held similar positions at Descartes, G-Log and Kewill (now BluJay). He has deep domain expertise in purchasing, sales and operations planning, all aspects of supply chain management, as well as transportation and distribution.
“The 3Gtms solution is fundamentally different than anything else on the market, and I’m thrilled to lead its growth beyond North America,” said van der Harst. “I’m also delighted to join a creative, customer-centric team that is changing what’s possible with TMS software.”
“Chris brings our customers a deep understanding of the market, its needs and what the trends are going forward,” said Mitch Weseley, CEO of 3Gtms. “This expertise, combined with his history of successful growth and leadership, will help broaden our fast growth and enable more organizations to differentiate themselves with our powerful solution.”
Chris van der Harst holds a bachelor’s degree in business economics, is APICS Certified in Production and Inventory Management (CPIM) and participated in the post-university MBA program in business economics from the University of Diepenbeek – Hasselt in Belgium.
About 3Gtms
3Gtms is the fastest growing, Tier-1 transportation management system (TMS) provider. It is dedicated to helping mid to large shippers and logistics service providers gain a competitive advantage through technology. Whether you move $5 million or $5 billion in freight, its 3G-TM solution seamlessly manages the full transportation lifecycle, including transportation planning and optimization, execution and settlement, empowering customers to make better shipping decisions while meeting their service goals. 3Gtms is dedicated to delighting its customers and as a result, holds a 100 percent customer satisfaction rate that is unmatched in the industry. For more information, visit: www.3gtms.com.
Media Contact
Chuck Fuerst
3Gtms, Inc.
203.567.4610, x443
[email protected]


Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
Italy Fines Apple €98.6 Million Over App Store Dominance
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
FDA Approves Mitapivat for Anemia in Thalassemia Patients
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 



